Testing the Right Target and Right Drug at the Right Stage-Reference-Cited by-同舟云学术

Testing the Right Target and Right Drug at the Right Stage

Published:2011-11-30 Issue:111 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sperling Reisa A.¹,Jack Clifford R.²,Aisen Paul S.³

Affiliation:

1. Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02446, USA.

2. Department of Radiology, Mayo Clinic, Rochester, MN 55902, USA.

3. Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA.

Abstract

Drugs aimed at the initial stages of the Alzheimer’s disease pathology should be tested a decade before the onset of dementia.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference36 articles.

1. Resolving controversies on the path to Alzheimer's therapeutics

2. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment

3. PET imaging of amyloid deposition in patients with mild cognitive impairment

4. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

5. CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Cited by 472 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing diagnostic biomarkers for Alzheimer's disease based on histone lactylation-related gene;Heliyon;2024-09

2. The Alzheimer's Disease Neuroimaging Initiative Clinical Core;Alzheimer's & Dementia;2024-08-13

3. AROMHA Brain Health Test: A Remote Olfactory Assessment as a Screen for Cognitive Impairment;2024-08-06

4. Two-Year Longitudinal Outcomes of Subjective Cognitive Decline in Hispanics Compared to Non-hispanic Whites;Journal of Geriatric Psychiatry and Neurology;2024-07-23

5. Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns;Alzheimer's Research & Therapy;2024-07-05